Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus Docetaxel in Advanced Non-squamous NSCLC
NCT03416231Phase 2Unknown
- Sponsor
- Affiliated Hospital of North Sichuan Medical College
- Start
- Nov 2016
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in non-small cell lung cancer (NSCLC), sponsored by Affiliated Hospital of North Sichuan Medical College. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03416231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03416231.